nbn Antibody

What are the primary applications for NBN antibodies in research?

NBN antibodies can be used across multiple experimental applications with varying dilution requirements. The most common applications include Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC), and Immunofluorescence (IF/ICC). For optimal results in each application, researchers should follow recommended dilution ranges that vary by both application and specific antibody. For example, rabbit polyclonal NBN antibodies typically require dilutions of 1:500-1:2400 for WB, 0.5-4.0 μg for IP (per 1.0-3.0 mg of total protein lysate), 1:500-1:2000 for IHC, and 1:500-1:2000 for IF/ICC applications . Rabbit recombinant antibodies may have different optimal dilution ranges, often 1:2000-1:10200 for WB applications . It's critical to titrate each antibody in your specific experimental system to determine optimal working concentrations.

How should NBN antibodies be stored to maintain reactivity?

Proper storage is crucial for maintaining antibody performance over time. Most NBN antibodies should be stored at -20°C and remain stable for approximately one year after shipment when stored properly . Storage buffers typically contain PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For mouse monoclonal NBN antibodies, the storage buffer may include 1% BSA in addition to glycerol and sodium azide . Importantly, repeated freeze-thaw cycles should be avoided to prevent antibody degradation. While aliquoting is generally recommended for antibodies, some manufacturers note that their specific formulations (particularly those with high glycerol content) do not require aliquoting for -20°C storage .

What are the species reactivity limitations for different NBN antibodies?

NBN antibodies vary in their cross-species reactivity, which is a critical consideration when designing experiments. Some antibodies, like certain rabbit polyclonal versions, demonstrate reactivity with human, mouse, and rat samples , making them versatile tools for comparative studies. In contrast, other antibodies may be limited to human samples only, as seen with some rabbit recombinant and mouse monoclonal NBN antibodies . When working with less common model organisms, it's essential to verify species reactivity before purchasing. Antibody datasheets typically distinguish between "Tested Reactivity" (experimentally confirmed) and "Cited Reactivity" (reported in literature), providing researchers with confidence levels for different species applications .

What positive controls are recommended for validating NBN antibody performance?

For effective experimental design, appropriate positive controls are essential. For Western blot applications, recommended positive controls include human cell lines such as HeLa, Jurkat, A549, and A431 cells . For tissue-based applications, human testis tissue has been validated for Western blot, while human stomach tissue is recommended for immunohistochemistry applications . When performing immunofluorescence studies, A549 cells serve as reliable positive controls . Using these validated positive controls allows researchers to confidently assess antibody performance before applying it to experimental samples, ensuring that negative results reflect biological reality rather than technical failures.

How can researchers optimize antibody-antigen detection when studying NBN in the context of the MRN complex?

Optimizing detection of NBN within the MRN complex requires consideration of several technical factors. First, understand that NBN functions as part of a larger protein complex with MRE11 and RAD50, which affects epitope accessibility. When designing co-immunoprecipitation experiments, use mild lysis buffers (e.g., those containing 0.5% NP-40 or 0.5% Triton X-100) to preserve protein-protein interactions within the complex. For immunofluorescence detection of NBN at DNA damage sites, pre-extraction with detergent before fixation can improve signal-to-noise ratio by removing soluble nucleoplasmic proteins. When performing IHC, antigen retrieval methods significantly impact NBN detection - data indicates that TE buffer at pH 9.0 provides optimal results, though citrate buffer at pH 6.0 may serve as an alternative . For complex formation analysis, consider dual immunostaining with antibodies against multiple MRN components, using different fluorophores to assess co-localization.

What technical considerations are important when interpreting observed molecular weight variations of NBN in Western blots?

While the calculated molecular weight of NBN is 85 kDa, the observed molecular weight typically ranges between 90-95 kDa across different experimental systems . This discrepancy results from post-translational modifications, primarily phosphorylation events that occur in response to DNA damage. When interpreting Western blot results, researchers should consider:

• Phosphorylation state: DNA damage activates ATM-dependent phosphorylation of NBN at multiple sites, causing reduced electrophoretic mobility and multiple bands that represent different phospho-isoforms.

• Sample preparation method: Harsh lysis conditions or excessive heating can cause protein degradation, generating lower molecular weight bands.

• Extraction protocol: Nuclear proteins like NBN require efficient nuclear extraction; insufficient extraction may result in weaker signals.

• Cell type-specific variations: Different cell types may express variant forms of NBN with slight molecular weight differences.

A methodological approach to resolving these variations includes running phosphatase-treated samples alongside experimental samples to identify mobility shifts due to phosphorylation, and using gradient gels (4-12%) to better resolve high molecular weight proteins.

How can researchers address epitope masking issues when detecting NBN in fixed tissues or cells?

Epitope masking is a significant challenge when detecting NBN, particularly in fixed samples where the MRN complex configuration may obscure antibody binding sites. To overcome this limitation:

What are the considerations for using NBN antibodies in studies of DNA damage response pathways?

When investigating DNA damage response (DDR) pathways using NBN antibodies, several methodological considerations become critical:

• Temporal dynamics: The phosphorylation state of NBN changes rapidly following DNA damage induction. Design time-course experiments with appropriate intervals (typically 15 min, 30 min, 1h, 3h, 6h, 24h post-damage) to capture these dynamics.

• Damage type specificity: Different DNA-damaging agents (ionizing radiation, UV, chemical agents) activate distinct DDR pathways. NBN responds differently to double-strand breaks versus other types of damage, so choose appropriate damage induction methods based on your research question.

• Cell cycle considerations: The MRN complex activity varies throughout the cell cycle, with NBN phosphorylation patterns differing between G1, S, and G2/M phases. Consider synchronizing cells or performing cell cycle analysis in parallel.

• Subcellular localization: Upon damage, NBN relocates to damage sites, forming foci that can be visualized by immunofluorescence. Optimization of fixation and permeabilization is critical for preserving these structures.

• Antibody selection: For phospho-specific detection, specialized phospho-NBN antibodies are required to detect specific phosphorylation sites (S278, S343, etc.) that become modified after damage induction.

What controls should be included when using NBN antibodies for quantitative applications?

Robust controls are essential for quantitative analysis of NBN expression or post-translational modifications:

• Positive controls: Include validated cell lines or tissues known to express NBN. HeLa cells, Jurkat cells, A549 cells, and human testis tissue have been verified as reliable positive controls for NBN detection .

• Negative controls: For antibody validation, consider:

  • Primary antibody omission control to assess secondary antibody specificity

  • Isotype controls (matching the host species and isotype of the NBN antibody)

  • Ideally, NBN-knockout or knockdown samples to confirm signal specificity

• Loading controls: For Western blot quantification, appropriate loading controls include nuclear proteins of similar abundance (e.g., lamin B1) rather than cytoplasmic housekeeping proteins when analyzing nuclear fractions.

• Technical replicates: Include at least three technical replicates for quantitative applications to address technical variability.

• Titration series: For absolute quantification, include a series of recombinant NBN standards at known concentrations.

What factors should be considered when selecting between polyclonal, monoclonal, and recombinant NBN antibodies?

The choice between different antibody types significantly impacts experimental outcomes:

Selection should be based on the specific research question, required sensitivity/specificity balance, and intended application. For detecting post-translational modifications or specific NBN conformational states, epitope-specific antibodies are essential.

How can researchers validate that their NBN antibody is detecting the correct target in new experimental systems?

Validating antibody specificity in new experimental systems requires a multi-faceted approach:

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight (90-95 kDa for NBN) , accounting for post-translational modifications.

• Genetic approaches:

  • RNA interference: Perform siRNA or shRNA knockdown of NBN and verify reduced signal intensity

  • CRISPR/Cas9 knockout: Generate NBN knockout cells/tissues as definitive negative controls

  • Overexpression: Transfect cells with NBN expression constructs and verify increased signal

• Orthogonal methods: Confirm results using alternative detection methods:

  • Detect NBN using antibodies targeting different epitopes

  • Use mass spectrometry to confirm protein identity in immunoprecipitated samples

  • Correlate protein detection with mRNA levels using RT-qPCR

• Peptide competition: Pre-incubate the antibody with immunizing peptide to block specific binding sites before application in your experiment.

• Cross-species validation: If the antibody is reported to work in multiple species, consistency of results across species increases confidence in specificity.

What special considerations apply when using NBN antibodies in proximity ligation assays or other interaction studies?

When studying protein-protein interactions involving NBN:

How should researchers address contradictory results when comparing data from different NBN antibodies?

When faced with contradictory results between different NBN antibodies:

• Epitope mapping: Determine the binding sites of each antibody on the NBN protein. Differences may result from:

  • Epitope masking in specific protein complexes

  • Post-translational modifications affecting epitope recognition

  • Conformational changes in different experimental conditions

• Validation hierarchy: Establish a validation hierarchy based on antibody quality indicators:

  • Knockout/knockdown validation provides the strongest evidence of specificity

  • Recombinant antibodies typically offer more consistent performance than polyclonals

  • Multiple citations supporting an antibody's use in your specific application

• Technical reconciliation: Adjust protocols to determine if contradictions are technically resolvable:

  • Test different sample preparation methods

  • Modify antigen retrieval conditions for IHC/IF

  • Adjust blocking and washing conditions to reduce non-specific binding

• Biological interpretation: Consider biological explanations for discrepancies:

  • Different NBN isoforms may exist in your experimental system

  • Cell-cycle dependent modifications might affect detection

  • Protein-protein interactions might mask specific epitopes in certain cellular contexts

• Report transparently: When publishing, clearly describe all antibodies used, their epitopes, and any discrepancies observed, along with your interpretation.

What methodological approach should be taken when analyzing NBN phosphorylation patterns in response to DNA damage?

Analyzing NBN phosphorylation requires careful experimental design and interpretation:

• Temporal considerations: NBN undergoes rapid phosphorylation following DNA damage, with different sites showing distinct kinetics. Design time-course experiments with appropriate sampling intervals (5 min, 15 min, 30 min, 1h, 3h, 6h, 24h post-damage) to capture phosphorylation dynamics.

• Site-specific detection: Use phospho-specific antibodies for key sites (e.g., S278, S343, S397) where available, or detect mobility shifts using standard NBN antibodies on Phos-tag™ gels for enhanced separation of phosphorylated forms.

• Phosphatase controls: Include phosphatase-treated samples to confirm that mobility shifts or phospho-antibody signals truly represent phosphorylation events.

• Kinase inhibitor studies: Include ATM inhibitors (e.g., KU-55933) to determine ATM-dependency of specific phosphorylation events, as many NBN phosphorylation sites are ATM-dependent.

• Quantification approaches:

  • For Western blots: Normalize phospho-NBN signal to total NBN rather than to housekeeping proteins

  • For immunofluorescence: Measure intensity, focus number, and co-localization with γH2AX or 53BP1 as indicators of NBN recruitment to damage sites

• Biological validation: Correlate phosphorylation patterns with functional outcomes (e.g., cell survival, DNA repair capacity) using NBN phospho-mutants.

What are the key considerations when using NBN antibodies to study chromatin-bound versus soluble fractions of the protein?

Distinguishing between different subcellular pools of NBN requires specialized methodological approaches:

• Fractionation protocols: Optimize subcellular fractionation to efficiently separate:

  • Cytoplasmic fraction (using low-salt buffers with mild detergents)

  • Nucleoplasmic fraction (using medium-salt extraction)

  • Chromatin-bound fraction (requiring nuclease treatment or high-salt extraction)

  • Matrix-associated fraction (resistant to both nuclease and salt extraction)

• Verification markers: Include markers for different fractions to verify fractionation quality:

  • Cytoplasmic: GAPDH, α-tubulin

  • Nucleoplasmic: soluble nuclear proteins like PARP1

  • Chromatin: Histones, particularly H3

• Extraction conditions: Different extraction conditions can affect the detection of NBN in specific fractions:

  • Pre-extraction with detergent prior to fixation for IF studies enhances visualization of chromatin-bound NBN

  • Crosslinking before extraction can trap transient chromatin interactions

• DNA damage considerations: DNA damage dramatically alters NBN distribution between fractions, increasing chromatin association. Include appropriate controls (damaged vs. undamaged) and time points to capture redistribution dynamics.

• Quantification approaches: For IF studies, high-resolution imaging combined with image analysis algorithms can distinguish nucleoplasmic from focal (damage-associated) NBN signals.

How should unexpected molecular weight bands be interpreted when using NBN antibodies in Western blot applications?

When unexpected bands appear in Western blots using NBN antibodies:

• Evaluate potential degradation products:

  • NBN is susceptible to proteolytic cleavage, especially during sample preparation

  • Include freshly prepared samples with robust protease inhibitor cocktails

  • Compare different lysis methods to determine if bands are preparation artifacts

• Consider post-translational modifications:

  • Phosphorylation causes upward shifts (above the expected 90-95 kDa range)

  • Ubiquitination produces ladder patterns or high-molecular-weight smears

  • Other modifications may cause subtler shifts

• Assess potential isoforms or splice variants:

  • Compare to known NBN transcript variants

  • Verify with RT-PCR using isoform-specific primers

• Rule out non-specific binding:

  • Test in NBN-depleted samples (siRNA, shRNA, or CRISPR knockout)

  • Perform peptide competition assays to identify specific versus non-specific bands

  • Compare patterns across multiple NBN antibodies targeting different epitopes

• Biological relevance assessment:

  • Determine if unexpected bands respond to experimental treatments in a manner consistent with NBN biology

  • Compare results across multiple cell types to identify cell-type specific patterns

  • Correlate with functional outcomes to assess potential biological significance

When reporting unexpected bands, clearly document their molecular weights, consistency across experiments, and any evidence for or against their relationship to NBN.

What steps should be taken when NBN antibodies fail to detect signal in Western blot applications?

When troubleshooting weak or absent NBN signals in Western blots:

• Sample preparation optimization:

  • Ensure complete nuclear extraction, as NBN is predominantly nuclear

  • Avoid excessive heating of samples (use 70°C instead of 95°C)

  • Include phosphatase inhibitors to preserve potentially important modifications

• Transfer efficiency verification:

  • Use reversible total protein stains (Ponceau S) to confirm protein transfer

  • Consider using PVDF membranes instead of nitrocellulose for potentially better retention

  • Optimize transfer conditions for high molecular weight proteins (90-95 kDa)

• Antibody optimization:

  • Test concentration series beyond recommended ranges (e.g., 1:250-1:5000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Try different blocking agents (BSA vs. milk, with milk potentially masking some epitopes)

• Detection system enhancement:

  • Use high-sensitivity ECL substrates for chemiluminescence

  • Consider fluorescent secondary antibodies for improved quantitative detection

  • Extend exposure times while monitoring background

• Positive control inclusion:

  • Run validated positive controls (HeLa, Jurkat, A549 cells)

  • Include purified recombinant NBN protein as absolute positive control

If these approaches fail, consider alternative antibodies targeting different epitopes, as certain domains may be inaccessible in your specific experimental context.

How can researchers optimize immunofluorescence protocols for detecting NBN at DNA damage sites?

To visualize NBN recruitment to DNA damage sites by immunofluorescence:

• Damage induction methods:

  • For global damage: UV irradiation, radiomimetic drugs

  • For focal damage: laser microirradiation or nuclease-based systems (e.g., FokI)

  • Include γH2AX staining to verify damage induction

• Fixation optimization:

  • Use freshly prepared 3-4% paraformaldehyde (10-15 minutes)

  • Avoid methanol fixation which can disrupt protein-protein interactions

  • Consider pre-extraction with 0.1-0.5% Triton X-100 before fixation to remove soluble nucleoplasmic proteins

• Permeabilization conditions:

  • 0.1-0.5% Triton X-100 for 5-10 minutes typically provides adequate permeabilization

  • For detection of chromatin-bound NBN, pre-extraction before fixation may be beneficial

• Antibody optimization:

  • Titrate antibody concentration (1:250-1:2000) for optimal signal-to-noise ratio

  • Extended primary antibody incubation (overnight at 4°C) may improve detection

  • Use highly cross-adsorbed secondary antibodies to minimize background

• Signal amplification strategies:

  • Consider tyramide signal amplification for weak signals

  • Use high-sensitivity detection systems for confocal microscopy

  • Optimize imaging parameters (exposure, gain, offset) for each channel

• Quantification approaches:

  • Foci counting algorithms with appropriate size and intensity thresholds

  • Co-localization analysis with other DDR factors (γH2AX, 53BP1, MRE11)

  • Time-course analysis to capture recruitment and resolution dynamics

What approaches can improve NBN detection in immunohistochemistry applications for formalin-fixed, paraffin-embedded tissues?

Optimizing NBN detection in FFPE tissue samples:

• Antigen retrieval optimization:

  • Use high-pH TE buffer (pH 9.0) as the primary method, with citrate buffer (pH 6.0) as an alternative

  • Extend retrieval time for heavily fixed tissues (20-30 minutes)

  • Consider pressure cooker-based retrieval for more efficient epitope unmasking

• Background reduction strategies:

  • Implement dual blocking (protein block followed by serum block)

  • Include avidin-biotin blocking if using biotin-based detection systems

  • Consider automated staining platforms for consistent washing

• Signal enhancement approaches:

  • Employ polymer-based detection systems for improved sensitivity

  • Consider tyramide signal amplification for low-abundance targets

  • Optimize chromogen development time with monitoring

• Controls and validation:

  • Include positive control tissues (human stomach tissue has been validated)

  • Use NBN-overexpressing and NBN-depleted xenografts as additional controls

  • Perform parallel staining with multiple NBN antibodies targeting different epitopes

• Counterstaining considerations:

  • Adjust hematoxylin intensity to maintain visibility of nuclear NBN staining

  • Consider fluorescent IHC for co-localization studies with other DDR factors

When quantifying IHC results, implement digital pathology approaches that can distinguish nuclear from cytoplasmic staining and account for staining intensity variations.